Danaher to acquire Masimo for $180/share cash, ~$9.9B enterprise value

DANAHER CORP /DE/

All-cash deal at $180/share; total enterprise value ~$9.9B including assumed debt.
Represents ~18x estimated 2027 EBITDA, or 15x including full annual synergies.
Masimo to operate as standalone company within Danaher's Diagnostics segment.
Expected to close H2 2026; subject to Masimo shareholder and regulatory approvals.
Expects $125M annual cost synergies and >$50M revenue synergies by year 5; EPS accretive $0.15–0.20 first year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.